Subjective well-being under the neuroleptic treatment and its relevance for compliance.
Standard
Subjective well-being under the neuroleptic treatment and its relevance for compliance. / Naber, Dieter; Karow, Anne; Lambert, Martin.
In: Acta Psychiatr Scand Suppl, Vol. 427, 2005, p. 29-34.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Subjective well-being under the neuroleptic treatment and its relevance for compliance.
AU - Naber, Dieter
AU - Karow, Anne
AU - Lambert, Martin
PY - 2005
Y1 - 2005
N2 - OBJECTIVE: To review the concept of 'subjective well-being under neuroleptic treatment', its development and clinical relevance,particularly regarding compliance. METHOD: The manuscript includes a review of the limited literature and recent open and controlled clinical trials. RESULTS: The patients' perspective of antipsychotic treatment was largely neglected for a long time. Scientific interest in this field of strong clinical relevance started mainly with the development of atypical antipsychotics. Recent research indicates that subjective well-being (SW) is a major determinant of medication compliance in schizophrenia. There are several self-report instruments with sufficient internal consistency and good construct validity. Effects of antipsychotic treatment on psychopathology and SW are only partly related. Most patients strongly prefer the atypical over typical antipsychotics. The assessment of SW is helpful for selecting the optimal drug for the individual patient. CONCLUSION: SW, under antipsychotic treatment, is a valid construct; its assessment provides an independent outcome variable, which is relevant to compliance.
AB - OBJECTIVE: To review the concept of 'subjective well-being under neuroleptic treatment', its development and clinical relevance,particularly regarding compliance. METHOD: The manuscript includes a review of the limited literature and recent open and controlled clinical trials. RESULTS: The patients' perspective of antipsychotic treatment was largely neglected for a long time. Scientific interest in this field of strong clinical relevance started mainly with the development of atypical antipsychotics. Recent research indicates that subjective well-being (SW) is a major determinant of medication compliance in schizophrenia. There are several self-report instruments with sufficient internal consistency and good construct validity. Effects of antipsychotic treatment on psychopathology and SW are only partly related. Most patients strongly prefer the atypical over typical antipsychotics. The assessment of SW is helpful for selecting the optimal drug for the individual patient. CONCLUSION: SW, under antipsychotic treatment, is a valid construct; its assessment provides an independent outcome variable, which is relevant to compliance.
M3 - SCORING: Zeitschriftenaufsatz
VL - 427
SP - 29
EP - 34
ER -
